Literature DB >> 19920181

The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding.

Rhonda C Kines1, Cynthia D Thompson, Douglas R Lowy, John T Schiller, Patricia M Day.   

Abstract

Using a murine challenge model, we previously determined that human papillomavirus (HPV) pseudovirions initially bind preferentially to the cervicovaginal basement membrane (BM) at sites of trauma. We now report that the capsids undergo a conformational change while bound to the BM that results in L2 cleavage by a proprotein convertase (PC), furin, and/or PC5/6, followed by the exposure of an N-terminal cross-neutralization L2 epitope and transfer of the capsids to the epithelial cell surface. Prevention of this exposure by PC inhibition results in detachment of the pseudovirions from the BM and their eventual loss from the tissue, thereby preventing infection. Pseudovirions whose L2 had been precleaved by furin can bypass the PC inhibition of binding and infectivity. Cleavage of heparan sulfate proteoglycans (HSPG) with heparinase III prevented infection and BM binding by the precleaved pseudovirions, but did not prevent them from binding robustly to cell surfaces. These results indicate that the infectious process has evolved so that the initial steps take place on the BM, in contrast to the typical viral infection that is initiated by binding to the cell surface. The data are consistent with a dynamic model of in vivo HPV infection in which a conformational change and PC cleavage on the BM allows transfer of virions from HSPG attachment factors to an L1-specific receptor on basal keratinocytes migrating into the site of trauma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19920181      PMCID: PMC2787115          DOI: 10.1073/pnas.0908502106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  'Shed' furin: mapping of the cleavage determinants and identification of its C-terminus.

Authors:  B Plaimauer; G Mohr; W Wernhart; M Himmelspach; F Dorner; U Schlokat
Journal:  Biochem J       Date:  2001-03-15       Impact factor: 3.857

Review 2.  Epidermal stem cells of the skin.

Authors:  Cédric Blanpain; Elaine Fuchs
Journal:  Annu Rev Cell Dev Biol       Date:  2006       Impact factor: 13.827

3.  Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection.

Authors:  Rebecca M Richards; Douglas R Lowy; John T Schiller; Patricia M Day
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

4.  Bovine papillomavirus genome elicits skin tumours in transgenic mice.

Authors:  M Lacey; S Alpert; D Hanahan
Journal:  Nature       Date:  1986 Aug 14-20       Impact factor: 49.962

5.  In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.

Authors:  R B Roden; H L Greenstone; R Kirnbauer; F P Booy; J Jessie; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

6.  Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4.

Authors:  L M Chandrachud; G J Grindlay; G M McGarvie; B W O'Neil; E R Wagner; W F Jarrett; M S Campo
Journal:  Virology       Date:  1995-08-01       Impact factor: 3.616

7.  Production of papillomavirus-based gene transfer vectors.

Authors:  Christopher B Buck; Cynthia D Thompson
Journal:  Curr Protoc Cell Biol       Date:  2007-12

8.  Human antibodies recognize multiple distinct type-specific and cross-reactive regions of the minor capsid proteins of human papillomavirus types 6 and 11.

Authors:  N Yaegashi; S A Jenison; M Batra; D A Galloway
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

9.  Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.

Authors:  Jeffrey N Roberts; Christopher B Buck; Cynthia D Thompson; Rhonda Kines; Marcelino Bernardo; Peter L Choyke; Douglas R Lowy; John T Schiller
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

10.  Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.

Authors:  Subhashini Jagu; Balasubramanyam Karanam; Ratish Gambhira; Sudha V Chivukula; Revathi J Chaganti; Douglas R Lowy; John T Schiller; Richard B S Roden
Journal:  J Natl Cancer Inst       Date:  2009-05-26       Impact factor: 13.506

View more
  138 in total

Review 1.  [HPV-associated squamous cell carcinogenesis].

Authors:  G Assmann; K Sotlar
Journal:  Pathologe       Date:  2011-09       Impact factor: 1.011

Review 2.  Vaccines to prevent infections by oncoviruses.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

3.  Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses.

Authors:  Manuela Donalisio; Marco Rusnati; Andrea Civra; Antonella Bugatti; Donatella Allemand; Giovanna Pirri; Andrea Giuliani; Santo Landolfo; David Lembo
Journal:  Antimicrob Agents Chemother       Date:  2010-07-19       Impact factor: 5.191

4.  HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions.

Authors:  Douglas R Lowy
Journal:  J Clin Invest       Date:  2016-01-04       Impact factor: 14.808

5.  Human papillomavirus capsids preferentially bind and infect tumor cells.

Authors:  Rhonda C Kines; Rebecca J Cerio; Jeffrey N Roberts; Cynthia D Thompson; Elisabet de Los Pinos; Douglas R Lowy; John T Schiller
Journal:  Int J Cancer       Date:  2015-10-27       Impact factor: 7.396

6.  A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.

Authors:  Patricia M Day; Yuk-Ying S Pang; Rhonda C Kines; Cynthia D Thompson; Douglas R Lowy; John T Schiller
Journal:  Clin Vaccine Immunol       Date:  2012-05-16

7.  High HPV16 E6 viral load in the oral cavity is associated with an increased number of bacteria: A preliminary study.

Authors:  Hideo Shigeishi; Masaru Sugiyama; Kouji Ohta; Sho Yokoyama; Miyuki Sakuma; Hiroshi Murozumi; Hiroki Kato; Masaaki Takechi
Journal:  Biomed Rep       Date:  2017-11-29

Review 8.  Concepts of papillomavirus entry into host cells.

Authors:  Patricia M Day; Mario Schelhaas
Journal:  Curr Opin Virol       Date:  2013-12-14       Impact factor: 7.090

Review 9.  The challenge of developing a herpes simplex virus 2 vaccine.

Authors:  Lesia K Dropulic; Jeffrey I Cohen
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

10.  Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen.

Authors:  Andrew G Diamos; Dalia Larios; Lauren Brown; Jacquelyn Kilbourne; Hyun Soon Kim; Divyasha Saxena; Kenneth E Palmer; Hugh S Mason
Journal:  Vaccine       Date:  2018-11-17       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.